Asthma-Related Health Outcomes Associated with Short-Acting β2-Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Global Program

Analysis (n=336,412 with linked hospital data) found that high use of short acting beta agonist inhaler was significantly associated with an increased risk of exacerbations, asthma-related primary care consultations and asthma-related hospital outpatient consultations.


Advances in Therapy